International Journal of Cancer最新文献

{"title":"Total neoadjuvant therapy in rectal cancer: The FOREST protocol, a patient-centered approach that clusters two cohorts with different outcomes.","authors":"Hector Guadalajara, Jose Luis Domínguez-Tristancho, Raquel Fuentes Mateo, Miguel Leon-Arellano, Raquel Sanz-Baro, Eleonora Geraldi, Ana Isabel Hormigo-Sanchez, Víctor Manuel Castellano Megías, Marta Pérez Cobos, Patricia Mellado Miras, Begoña Lopez-Botet Zulueta, Mariano Garcia-Arranz, Jesus García Foncillas, Cristina Caramés, Damián García-Olmo","doi":"10.1002/ijc.70126","DOIUrl":"https://doi.org/10.1002/ijc.70126","url":null,"abstract":"<p><p>Rectal cancer treatment has evolved toward individualized strategies that emphasize organ preservation and tailored therapeutic approaches. The FOREST protocol combines total neoadjuvant therapy (TNT), early response evaluation, and prehabilitation within a comprehensive framework designed to optimize outcomes while minimizing overtreatment. In this single-center prospective study, 67 patients with rectal cancer (T1-T4, any N) were enrolled between April 2020 and December 2022. Treatment decisions-radical surgery (RS), watch and wait (WW), or local surgery (LS)-were guided by early and final response assessments. Outcomes were analyzed under an intention-to-treat (ITT) approach, with a median follow-up of 968 days (range: 440-2015). Final treatments included RS in 47.8% (n = 32), WW in 50.7% (n = 34), and LS in 1.5% (n = 1). Completion of TNT was achieved in 79.1% of patients. Organ preservation was accomplished in 44.8% (30/67 = 44.8%, with 34 WW and 1 LS). Systemic recurrence occurred in 22.4% of patients, surpassing the rate of local regrowth or persistence (17.9%). DFS in the WW group (65.7%) was comparable to that of the RS group (71.4%), while OS significantly favored WW (100% vs. 80.7%, p = .014). The FOREST protocol demonstrates that integrating TNT with response-guided strategies is feasible and can lead to high organ preservation rates and favorable oncologic outcomes. A key strength of the protocol is its ability to identify two distinct patient cohorts based on response evaluation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.","authors":"Ria Chopra, Haolong Li, Wenjuan Xie, Daniel Hau Tak Lam, Franky Leung Chan","doi":"10.1002/ijc.70149","DOIUrl":"https://doi.org/10.1002/ijc.70149","url":null,"abstract":"<p><p>Disruption of circadian rhythms due to night-shift work is classified as a probable carcinogen for cancers of the breast, prostate, and colorectum by the International Agency for Research on Cancer. Global epidemiological studies link chronic circadian clock disruption to increased risk of prostate cancer via hormone and metabolic dysregulation. This study investigated and compared the circadian expression patterns of core-circadian controlled genes (CCCGs) and nuclear receptors (NRs) under a normal 12-h light/dark cycle in normal mouse prostate and advanced androgen-insensitive prostate tumors derived from a transgenic mouse model of prostate adenocarcinoma (TGMAP). Our results showed that a total of eight CCCGs and 22 NRs exhibited rhythmic oscillations in the normal mouse prostate. In contrast, the rhythmic expressions of CCCGs and NRs were significantly disrupted in TGMAP prostate tumors, with a concurrent loss of androgen receptor expression. Circadian administration of cisplatin at a specific morning time point (chrono-chemotherapy), as applied in TGMAP tumor-bearing mice, demonstrated optimal antitumor efficacy, which correlated with the circadian rhythmic expression of DNA damage repair genes. Finally, we showed that chronic jet-lag conditions could promote the oncogenic growth of hormone-sensitive VCaP-derived xenograft tumors, with a correlation to elevated serum androgen levels and increased expression of enzyme genes involved in intratumoral androgen biosynthesis. Together, this study demonstrated that advanced prostate tumors exhibited dysregulated circadian transcriptional networks, as shown by their disrupted expression of CCCGs and NRs. The potential therapeutic application of chrono-chemotherapy in advanced prostate cancer management and the disruption of circadian rhythms under chronic jet-lag conditions could enhance prostate cancer growth.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.","authors":"Zichen Zhao, Hao Rong, Mengxia Li, Yong Xu, Long Tian, Xiaoming Qiu, Hu Liao, Yalun Li, Ke Wang, Xiaojun Tang, Panwen Tian, Daxing Zhu, Qinghua Zhou, Yan Zhang","doi":"10.1002/ijc.70153","DOIUrl":"https://doi.org/10.1002/ijc.70153","url":null,"abstract":"<p><p>The clinical value of neoadjuvant immunochemotherapy in limited-stage small-cell lung cancer (LS-SCLC) remains poorly defined, with limited comparative data available against concurrent chemoradiotherapy (CCRT). This retrospective multicenter study evaluated the efficacy and safety of neoadjuvant immunochemotherapy, chemotherapy, and CCRT in treatment-naive patients with potentially resectable SCLC. A total of 139 patients treated between February 2019 and December 2023 were included: 55 received CCRT, and 84 underwent neoadjuvant therapy followed by surgery (28 immunochemotherapy, 56 chemotherapy). Complete (R0) resection was achieved in all surgical cases. The pathological complete response (pCR) rate was significantly higher in the immunochemotherapy group than in the chemotherapy group (35.7% vs. 7.1%, p < .05), as was the major pathological response (MPR) rate (53.6% vs. 12.5%, p < .05). Adverse events were acceptable in the three groups. After propensity score matching (PSM), 24 patients from each group were included for survival analysis. Although median progression-free survival (PFS) and overall survival (OS) were not reached in the immunochemotherapy group, Kaplan-Meier analysis showed significantly prolonged PFS and OS compared with both chemotherapy and CCRT. These results suggest that neoadjuvant immunochemotherapy is a safe and effective treatment strategy for LS-SCLC and merits further investigation in prospective trials.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term impact of stressful life events on breast cancer risk: A 36-year genetically informed prospective study in the Finnish Twin Cohort.","authors":"Elissar Azzi, Hannes Bode, Teemu Palviainen, Mikaela Hukkanen, Miina Ollikainen, Jaakko Kaprio","doi":"10.1002/ijc.70154","DOIUrl":"https://doi.org/10.1002/ijc.70154","url":null,"abstract":"<p><p>Breast cancer (BC) is influenced by both genetic and environmental factors, but the long-term impact of stressful life events (SLEs) remains unclear. We examine the association between SLEs and BC risk using cohort and twin-pair analyses with 36 years of follow-up in the Finnish Twin Cohort, including 10,342 women and 719 BC cases. SLEs were assessed in 1981 by a questionnaire, while cancer incidence and mortality data were obtained from Finnish registries. Polygenic risk score for breast cancer (PRS-BC) and DNA methylation (DNAm) profiling were used to explore the underlying genetic and epigenetic factors. Cox proportional hazards models showed a significant association between SLEs and breast cancer risk (HR = 1.05 per event, 95% CI: 1.02-1.08). As few as 2-3 SLEs were associated with a 24% increased risk (HR = 1.24, 95% CI: 1.00-1.54), emphasizing the impact of even a modest number of events. Within-pair analyses in monozygotic twins suggested non-genetic factors mediate this association. Stratification by birth cohort revealed a stronger effect in women born before 1950 (HR = 1.07, 95% CI: 1.01-1.12). While PRS-BC was not significantly associated with breast cancer risk, DNAm analysis identified 42 BC-associated CpG sites linked to both SLE exposure and environmental BC risk. These findings were replicated in cancer-free twin pairs, supporting epigenetic rather than genetic mediation. SLEs may be an independent risk factor for breast cancer, potentially mediated by epigenetic mechanisms. Further research is needed to explore the functional consequences of stress-related epigenetic changes and their role in BC development across generations.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative prediction of early recurrence in pancreatic cancer: A novel clinical-radiomics model.","authors":"Yiting Xu, Ming Chen, Yang Chen, Zhihang Cai, Zongyan Luo, Bing Wang, Gaowei Jin, Yangyang Wang, Xu Han, Xing Xue, Liying Liu, Pu Liu, Zhihao Ma, Huan Luo, Tingbo Liang, Qi Zhang","doi":"10.1002/ijc.70142","DOIUrl":"https://doi.org/10.1002/ijc.70142","url":null,"abstract":"<p><p>Early postoperative recurrence critically impacts pancreatic ductal adenocarcinoma prognosis, yet comprehensive preoperative prediction models remain underexplored. In this two-center retrospective study of 895 treatment-naïve PDAC patients who underwent direct resection (training n = 567; internal validation n = 241; external validation n = 87), we defined early recurrence as tumor relapse within 6 months of surgery. We first built a clinical model using logistic regression to select clinical variables and a radiomics model by applying LASSO regression to features extracted from preoperative CT images, then combined these into an integrated clinical-radiomics model via logistic regression. Of the 895 patients (64.4% male; mean age 64.4 ± 8.7 years), 213 (23.8%) experienced early recurrence. Four clinical variables (gender, CA125, radiologic N stage, adjuvant treatment) and 29 radiomics features were selected for the final model, which achieved area under the curve values of 0.862 (95% CI 0.828-0.896) in the training cohort, 0.843 (0.785-0.901) in internal validation, and 0.848 (0.748-0.949) in external validation-each outperforming either the clinical or radiomics model alone. Stratified analyses confirmed robustness across subgroups, and patients classified as high risk by the model had significantly shorter disease-free and overall survival (both p < .001). This clinical-radiomics model offers a preoperative tool to identify PDAC patients at high risk of early postoperative recurrence, thereby supporting personalized treatment planning beyond immediate surgery.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in cancer diagnoses and stage distribution during the COVID-19 pandemic in the United States, 2019-2022.","authors":"Nuo Nova Yang, Qinjin Fan, Leticia Nogueira, Changchuan Jiang, Hyuna Sung, Elizabeth J Schafer, K Robin Yabroff, Xuesong Han","doi":"10.1002/ijc.70144","DOIUrl":"https://doi.org/10.1002/ijc.70144","url":null,"abstract":"<p><p>Underdiagnoses and decreases in early-stage diagnoses occurred during 2020 in the United States, the first year of the COVID-19 pandemic, particularly in medically underserved populations. This study examined changes in cancer diagnoses and stage distribution in 2021 and 2022 among adults using newly released nationwide cancer registry data. Adults aged ≥18 years newly diagnosed with first primary malignant cancers between January 2019 and December 2022 from 50 US states and the District of Columbia were identified from the National Cancer Database. We calculated monthly diagnoses, stage distribution, and adjusted odds ratios of the percentage of stage I cancer diagnoses in 2020, 2021, and 2022 compared with 2019, controlling for sociodemographic and clinical factors and stratified by cancer type. A total of 3,342,235 individuals newly diagnosed with cancer were included in the study, of whom 863,793 were diagnosed in 2019, 787,366 in 2020, 872,638 in 2021, and 818,438 in 2022. The percentage of stage I diagnosis in 2021 (39.0%) and 2022 (39.2%) was higher than in 2020 (38.2%), but still lower than in 2019 (39.6%). Patterns of stage I diagnoses varied by cancer type. This cross-sectional study found that overall cancer diagnoses and the percentage of stage I diagnoses increased in 2021 and 2022, but have not returned to the pre-pandemic levels, with exceptions for some cancer types. Ongoing monitoring is warranted to address the long-term impact of the COVID-19 pandemic on cancer diagnosis and outcomes in the United States.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overdiagnosis of thyroid cancer in the United States: Improved estimates based on the SEER registries during 2000-2019.","authors":"Minlu Zhang, Dongchen Xie, Yi Hu, Guoyou Qin, Wanghong Xu","doi":"10.1002/ijc.70143","DOIUrl":"https://doi.org/10.1002/ijc.70143","url":null,"abstract":"<p><p>The rising thyroid cancer (TC) incidence is largely attributed to overdiagnosis, primarily due to widespread use of sensitive imaging technologies. Prior estimates of overdiagnosis relied on generalized assumptions that may not account for population-specific risk exposures and diagnostic trends. This study aims to provide more accurate estimates by addressing previous methodological limitations. In this population-based study, we obtained aggregated data on the incidence and mortality of TC during 2000 to 2019 from the Surveillance, Epidemiology, and End Results 22 (SEER-22) and SEER-17. The age-standardized incidence (ASIR) and mortality rates (ASMR) were calculated by sex, histology, stage, and 5-year periods. Overdiagnosis rates were estimated using population-specific parameters derived from the multistage model of carcinogenesis. The ASIR of papillary thyroid cancer (PTC) and non-PTC increased rapidly in both men and women during 2000 to 2014 and stabilized thereafter, whereas the ASMR remained relatively unchanged. The overdiagnosis was mainly observed for differentiated TC subtypes, including PTC and follicular TC. A total of 50,239 (63.5%) men and 203,429 (79.5%) women cases of PTC were attributable to overdiagnosis, accounting for 73.9% of early-stage PTC in men and 85.2% in women. In contrast, no significant overdiagnosis was observed for non-PTC overall, with an 11.0% underdiagnosis rate in men and a 19.2% overdiagnosis rate in women. This study presents refined estimates of TC overdiagnosis and highlights the continued impact of early detection on incidence trends. The findings support the need for risk stratification for TC screening and management to minimize the potential overtreatment while ensuring the timely detection of clinically significant cases.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany.","authors":"Alexander Fabian, Alexander Rühle, Gregor Liegl, Justus Domschikowski, Maike Trommer, Simone Ferdinandus, Jan-Niklas Becker, Georg Wurschi, Simon Boeke, Mathias Sonnhoff, Christoph Grott, Lukas Käsmann, Melanie Schneider, Sandra Freitag-Wolf, Nils H Nicolay, David Krug, Sandra Nolte","doi":"10.1002/ijc.70152","DOIUrl":"https://doi.org/10.1002/ijc.70152","url":null,"abstract":"<p><p>Germany has one of the highest cancer incidence rates in Europe. Radiotherapy is essential for patients with cancer as 50% have an evidence-based indication for radiotherapy. However, it is unknown how health-related quality of life (HRQoL) of cancer patients undergoing radiotherapy compares to the general population in Germany. Therefore, we conducted a secondary analysis by pooling cross-sectional individual-level data from a multicenter cohort of cancer patients (n = 1052) undergoing radiotherapy across Germany and a normative sample from the German general population (n = 1006). We used the EORTC QLQ-C30 to measure global HRQoL (range: 0-100). Higher scores indicate higher HRQoL. We used ANOVA for univariable and ANCOVA with predefined covariates for multivariable analyses. As per univariable analysis, cancer patients had significantly lower global HRQoL compared with the general population (mean [M] = 54.6 vs. M = 65.9; p < .001). This difference was smaller but persisted in the multivariable analysis (M = 56.5 vs. M = 63.5; p < .001). Multivariable analyses stratified by education showed that HRQoL was only lower in cancer patients with medium (M = 56.2 vs. M = 63.0; p < .001) or high education (M = 57.0 vs. M = 66.5; p < .001) compared with the general population. The minimal important difference threshold of seven points was only met in the group with high education. In conclusion, there may be a meaningful gap in HRQoL of cancer patients at the end of radiotherapy compared with the general population, mainly in patients with higher educational levels. Upon validation, this would highlight the need for supportive care and optimized radiotherapy strategies to eventually close the HRQoL gap.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry.","authors":"Lydia G van der Geest, Marianne van der Mark, Joanne Verheij, Arantza Farina Sarasqueta, Judith de Vos-Geelen, Marc G Besselink, Vincent E de Meijer, Ignace H J T de Hingh, Bert A Bonsing, Philip R de Reuver, Francois E J A Willemssen, Pauline A J Vissers, Otto Visser","doi":"10.1002/ijc.70145","DOIUrl":"https://doi.org/10.1002/ijc.70145","url":null,"abstract":"<p><p>Given the poor survival and relatively poor performance of hepato-pancreato-biliary (HPB) cancers on data quality indicators for cancer registries, we assessed trends in incidence, survival, and data quality of HPB cancers within the Netherlands Cancer Registry (NCR). All primary solid liver, gallbladder, biliary tract, and pancreatic cancers (topography C22-23-24-25) diagnosed between 1989 and 2022 were included (n = 109,552). Cancer mortality data were obtained from Statistics Netherlands. For incidence and mortality, revised European Age-Standardised Rates, and for survival, age-standardised 5-year relative survival (AS-5yRS) were calculated. Over time, incidence rates increased for liver (males: 3.0 to 8.2/100,000; females 1.2 to 3.9/100,000), pancreatic (males: 15.8 to 18.5/100,000; females: 11.1 to 15.3/100,000), and biliary tract cancers in males (3.9 to 4.9/100,000; not females: 3.3 to 2.9/100,000). Gallbladder cancer incidence decreased until 2005 (males: 1.5 to 0.8/100,000, females 4.0 to 1.5/100,000). Mortality trends mirrored incidence patterns, with smaller increases. AS-5yRS improved across all HPB cancers with the largest increase in liver (males: 3.4% to 20.8%; females: 6.7% to 18.3%) and pancreatic cancers (males: 2.3% to 10.4%; females: 3.5% to 11.3%). Since 2010, survival gains for gallbladder (males: 8.4% to 16.3%; females: 12.2% to 15.8%) and biliary tract cancers (males: 11.7% to 19.1%; females: 10.7% to 15.6%) have stagnated. Mortality-to-Incidence ratios versus 5-year relative survival for liver and pancreatic cancers improved toward equilibrium. Data quality improved (e.g., autopsy, unspecified morphology) or remained stable (multiple primaries). Both incidence and survival rates of primary HPB cancers have increased over time. Increased completeness of incidence data was attributed to changed notification sources.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.","authors":"Karoline Andersen, Jesper Bonde, Marianne Waldstrøm, Maria Vad Jakobsen, Philippe Lamy, Helle Pedersen, Sara Bønløkke, Magnus Stougaard, Torben Steiniche","doi":"10.1002/ijc.70148","DOIUrl":"https://doi.org/10.1002/ijc.70148","url":null,"abstract":"<p><p>The carcinogenicity of HPV genotypes is well established. However, HPV genotypes have sublineages with individual risk profiles, and these are much less described with respect to carcinogenicity. Research to characterize HPV sublineages by next-generation sequencing (NGS) on screening-derived liquid-based cytology (LBC) samples is limited because of the technical and quality assurance challenging nature of sublineage analysis. This study aimed to evaluate the feasibility of detecting HPV sublineages from 14 HPV genotypes in SurePath LBC samples from Danish cervical cancer screening. We included 41 HPV plasmids (the Global HPV LabNet DNA Genotyping Proficiency Panel 2023) to quality assure the NGS approach and 120 SurePath LBC samples from the screening program for proof of concept. Our results of the HPV plasmids showed the correct sublineage for all included HPV genotypes except for HPV68b, where the coverage was inadequate for sublineage analysis. The NGS analysis enabled HPV sublineage analysis in 99.1% (112/113) of HPV-positive SurePath LBC samples. Sublineages belonging to the A lineage were most frequent for HPV16, 18, 31, 33, 35, 39, 51, 52, 58, 59, and 68, while B-type sublineages showed the highest frequency in HPV45, 56, and 66. The most diverse sublineage data was obtained for HPV31 with sublineages from the A, B, and C lineages. In conclusion, our method enables the identification of HPV sublineages in SurePath LBC screening samples. This information can be used in future studies to determine the usefulness of HPV sublineage analysis in screening settings for risk stratification and clinical management of HPV-positive women.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}